Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic

References

• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.21095116
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Armitage JO. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11(6):511–513. doi:10.1200/JOP.2015.00674229424584
   PubMed Web of Science ®Google Scholar
• Yang BB, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy. 2012;58(5):387–398. doi:10.1159/00034562623296266
   PubMed Web of Science ®Google Scholar
• Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25(11):3295–3304. doi:10.1007/s00520-017-3842-128842778
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693. doi:10.1182/blood.V99.8.268511929754
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925. doi:10.1056/NEJMoa130839224224624
   PubMed Web of Science ®Google Scholar
• Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–514. doi:10.1111/bjh.1346325907897
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416. doi:10.1056/NEJMoa121456123574119
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM1993093032914028141877
   PubMed Web of Science ®Google Scholar
• Huang W, Liu J, Zeng Y, et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2018;82(4):607–613. doi:10.1007/s00280-018-3639-z30043207
   PubMed Web of Science ®Google Scholar
• Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23(2):525–545. doi:10.1007/s00520-014-2457-z25284721
   PubMed Web of Science ®Google Scholar
• Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11):1816–1829. doi:10.1007/s12325-018-0798-630298233
   PubMed Web of Science ®Google Scholar
• Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514–519. doi:10.1200/JCO.2003.03.04012560443
   PubMed Web of Science ®Google Scholar
• Chan A, Leng XZ, Chiang JY, et al. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol. 2011;7(1):75–81. doi:10.1111/j.1743-7563.2010.01355.x21332654
   PubMed Web of Science ®Google Scholar
• Ng JH, Ang XY, Tan SH, et al. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin’s lymphoma patients receiving pegfilgrastim. Acta Haematol. 2011;125(3):107–114. doi:10.1159/00032154521109731
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617. doi:10.1016/S2352-3026(18)30177-730501868
   PubMed Web of Science ®Google Scholar
• Miyake O, Murata K, Tanaka S, et al. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol. 2018;48(5):410–416. doi:10.1093/jjco/hyy03029590407
   PubMed Web of Science ®Google Scholar
• Perrier L, Lefranc A, Pérol D, et al. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy. 2013;11(2):12. doi:10.1007/s40258-013-0011-7
   Google Scholar